Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)

In plain English

National Institutes of Health (Department of Health and Human Services) has announced this as a forecast: an opportunity it expects to post. It is not open for applications yet. Estimated posting date: Oct 15, 2025 (this estimate has passed and the agency has not posted it yet). Estimated application due date: Feb 17, 2026.

The listing does not state award amounts or the number of awards.

Eligible applicant types include nonprofits, small businesses, for-profit companies, state governments, local governments, tribal governments & organizations, colleges & universities, school districts and public housing authorities.

The listing says cost sharing or matching is not required.

Built only from the fields in the Grants.gov listing. Always confirm on the official listing.

Browse similar: Nonprofits · Small businesses · For-profit companies · State governments · Local governments · Tribal governments & organizations · Colleges & universities · School districts · Public housing authorities

• State governments
• County governments
• Independent school districts
• Public and state-controlled institutions of higher education
• Native American tribal governments (federally recognized)
• Public housing authorities / Indian housing authorities
• Native American tribal organizations (other than federally recognized tribal governments)
• Nonprofits with 501(c)(3) status (other than institutions of higher education)
• Private institutions of higher education
• For-profit organizations other than small businesses
• Small businesses

Excerpt from the official forecast on Grants.gov (shortened; read the full text on the official listing):

The National Center for Advancing Translational Science (NCATS) seeks to advance its mission by advancing research on extracellular vesicles (EVs) and their use as therapeutics in the field of regenerative medicine. The main objective of this program, Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe) , is to support the translation of EV-based therapeutics in regenerative medicine. EVs, like exosomes and microvesicles, are crucial mediators of intercellular communication, carrying diverse cargo like proteins, nucleic acids, and lipids. In regenerative medicine, EVs play a significant role by influencing cellular behaviors during tissue repair and regeneration. Due to their natural function in intercellular communication, EVs represent a novel, cell-free, therapeutic tool. …

Read the full forecast on Grants.gov →